Chapter 1
Stress

!"#$%&'$(')(*+,"--(
./0!*(*1231(4"#$"4(-+,"--5(6(/-(+7"($'$-8"9%#9(
,"-8'$-"(')(+7"(:'4;(+'(8'$(%+?@(
A/2B1C(D/00E0(#,-+(4"-9,%:"4(+7"(:'4;F-(,"N`9%"$+(-'9%$"D/+0"'8',;15$

$

PD/+0"'8',;1$')>$0"'8',;1$:/'&0$+?$8(,7(.$1D10#,5$
$
• !"#$JOF%O6$BQB!GF$(1$0"#$1#'0$+?$+;&$#,+@+)1$:?#'&$7+>D$
• 6+,/8#9$.+88#.@+)$+?$)#;&+)1$1#&C()=$'1$'$/+()0$+?$.+)C#&=#).#$
?+&$1(=)'81$?&+,$0"#$+;01(>#$*+&8>$')>$0"#$()0#&)'8$#)C(&+),#)0$
• O?$UKB$>+#1$)+0$#9.(0#$0"#$)#;&+)$+?$0"#$.+&0#9#&$'&+;1#>$
.+&0#9$
801$()$>(W.;80D$()$8#'&)()=$.+&0#9$
801$()$"D/#&$C(=(8').#$')>$l#11)#11$
')>$"D/#&'.@C(0D$
ML!G2$P;,')$7#"'C(+&$*'1$0"+;="0$0+$7#$'$?;).@+)$+?$+)#$'&#'$+?$0"#$7&'()$+&$
0"#$+0"#&S$M+*(8D$@11;#1$')>$'&#$
.'&&(#>$0"&+;="$0"#$.(&.;8'0+&D$1D10#,$0+$C'&(+;1$0'&=#01$
• G)>+.&()#$1D10#,$().8;>#1$0"#$/(0;(0'&D$
ML!G2$!"#1#$"+&,+)#1$."')=#$?;).@+)$+?$7+>(8D$@11;#1$')>$'&#$.'&&(#>$

0"&+;="$0"#$.(&.;8'0+&D$1D10#,$0+$C'&(+;1$0'&=#01S$
$

!"#$G)>+.&()#$BD10#,$6+)0Z>[SS$
K>&#)'8$=8')>1$.+)1(101$+?2$$
45 L;0#&$6+&0#9$$$$1#.#1$>(R#&#)0$"+&,+)#1$
A5 O))#&$F#>;88'$$
KHUGMKJ$6LU!G\$1#.#1$/'&01$+?$0"#$'>&#)'8$=8')>$
K>&#)'8$.+&0#9$1#.#1$!"#$%$%&'$%()*$:&#=;8'0#1$,#0'7+8(1,$+?$=8;.+1#5$')>$
+(,-&."%$%&'$%()*/0&#=;8'0#1$7'8').#$7#0*##)$1+>(;,$]$/+0'11(;,5/
• E&(,'&D$=8;.+.+&@.+(>$(1$$%&'*%"/
• E&(,'&D$,()#&'8+.+&@.+(>$(1$.")%*1-&%,-//
• 6+&@1+8$/&+C(>#1$?;#8$?+&$^_="03+&3`(="0a$'.@+)$
• K8>+10#&+)#$().&#'1#1$78++>$/&#$0+$/&#/'&#$?+&$'.@+)$

6'0#."+8',()#1$
• K>&#)'8$,#>;88'$1#.#1$-2(,-23&(,-$:'>&#)'8()5$')>$
)+&#/()#/"&()#$:)+&'>&#)'8()5$
• O))#&$/+&@+)$+?$0"#$'>&#)'8$=8')>1$1#.#1$.'0#."+8',()#1$
• GR#.01$&#,'()$4b$@,#1$8+)=#&$0"')$'>&#)'8$.+&@.+(>1$')>$
"+&,+)#1$8#'>1$0+$0"#$?+88+*()=$."')=#1$*(0"()$0"#$7+>D$2$

!
!
!
!

Increased heart rate
Increased stroke force
Dilation of coronary arteries Dilation of bronchial tubes

!
!
!

Increased basal metabolic rate Constriction of vessels to skin of arms, legs, muscles
Increased O2 consumption

!"#$K;0+)+,(.$M#&C+;1$BD10#,$
• KMB$(1$'.@C'0#>$7D$*"'0c$
PD/+0"'8',;1$
• !*+$/'&01$
– BD,/'0"#@.$:
/+)1(78#$?+&$#9/#)>()=$#)#&=D$7#0*##)$0"#$7+>D$.#881$')>$+&=')1$0"'0$
.+,,;)(.'0#$*(0"$0"#$#90#&)'8$#)C(&+),#)0$
• B0$+)$0"#$.(&.;8'0+&D$1D10#,$,'D$.';1#$#'1#$+?$
!"#$!%&'()(*+,!-./,,&'(
• %+0"$.')$.+)10&(.0$78++>$C#11#81$78++>$
/&#$
• P#'&0$
/+)>1$*(0"$().&#'1#>$?+&.#$+?$.+)0&'.@+)$
• 6"+8#10#&+8$')>$?&##$?'XD$'.(>1$().&#'1#$&(1Y$+?$"#'&0$
>(1#'1#$

!"#$N'10&+()0#1@)'8$BD10#,$
• U#1/+)1(78#$?+&$>(=#1@+)$
• B0$&#>;.#1$1'8(C'$/&+>;.@+)$')>$().&#'1#1$"D>&+."8+&(.$
'.(>$/&+>;.@+)$
• I8.#&1$.')$>#C#8+/$
• B0$.')$'80#&$&"D0",(.$,+C#,#)0$+?$?++>$>(1#'1#1$

!"#$F;1.8#1$
B0$
801$()$0#)1()=$0+$0"#$7+)#1$
B,++0"$F;1.8#1$.+)0&+8$0"#$.+)0&'.@+)$+?$()0#&)'8$+&=')1$
B,++0"$,;1.8#1$+?$10+,'."$*'881$.+)0&'.0$8#'>1$0+$
10+,'."'."#1$
• B,++0"$F;1.8#1$+?$()0#1@)#1$.+)0&'.0$8#'>1$0+$>('&&"#'$
•
•
•
•
•

!"#$BY()$
• O)C+8C#>$*(0"$10$
/+)1#$
• !#,/#&'0;&#$')>$#8#.0&(.'8$.+)>;.@+)$
'R#.0#>$
– BY()$0#,/#&'0;&#$+)$0"#$1;&?'.#$>&+/1$:.+8>#&5$

• B0$.';1#1$().&#'1#>$/#&1/(&'@+)$:.8',,D5$
• V'1+.+)10&(.@+)$+..;&1$>;&()=$10-0,394+$/0,5+$-81-,5+$65$4,$
@+541,9$58A54273+5$=,1+6:7$4,$40+$A,@9E$
• #$(+..5$$
'$49-+$,=$.9>-0,394+$/0,5+$-81-,5+$65$4,$@+541,9$
58A54273+5$=,1+6:7$4,$40+$A,@9$A9$-87348167:$67H2@+@$
A,@9$3+..5$27@$C6..67:$40+$3+..5$27@$40+$=,1+6:7$58A54273+$
• K$(+..5$
#9-+$,=$.9>-0,394+$4024$-1,@83+5$27;A,@6+5$

)48@6+5$,=$*+15,72.649$27@$!+2.40$
)42485$
• Hans Eysenck (1988) demonstrated personality traits leading to cancer and heart disease
• Research suggests that there is:
A CANCER-PRONE Personality: unassertive, overly patient, avoids conflict, fails to express negative emotions (connect with type a/b personality)
A HEART DISEASE-PRONE Personality: angry, hostile, aggressive

$